# Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

> **NCT02339558** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Nasopharyngeal Nonkeratinizing Carcinoma
- Recurrent Nasopharynx Carcinoma
- Stage III Nasopharyngeal Carcinoma AJCC v7
- Stage IV Nasopharyngeal Carcinoma AJCC v7
- Stage IVA Nasopharyngeal Carcinoma AJCC v7
- Stage IVB Nasopharyngeal Carcinoma AJCC v7
- Stage IVC Nasopharyngeal Carcinoma AJCC v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02339558
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-21
- **Primary completion:** 2018-06-16
- **Final completion:** —
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02339558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02339558, "Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02339558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*